Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021

Global CRPC treatment market forecast

According to CRPC treatment market insights, the global castration-resistant prostate cancer (CRPC) treatment market will grow at a CAGR of more than 9% during the forecast period. The growing preference for hormonal therapy acts as one of the key drivers for the castration-resistant prostate cancer treatment industry growth during the predicted period. Prostate cancer can occur due to the abnormal rise in testosterone level. This compels physicians to develop hormone therapies. Hormone therapies are the most preferred therapy for treating CRPC because they reduce the growth of prostate cancer cells by controlling the secretion of testosterone. Luteinizing hormone blockers, gonadotropin-releasing hormone (GnRH) blockers, antiandrogens, and abiraterone are some of the hormone therapies used as a treatment for CRPC.

Get A Free Sample

The emergence of targeted therapies and immunotherapies is one of the key CPRC treatment market trends that will gain traction in the market in the forthcoming years. The adoption of immunotherapies such as immune checkpoint inhibitors and vaccines is increasing in the treatment of CRPC because they have high efficacy and exhibit limited side effects.

Competitive landscape and key vendors

The global CRPC treatment market is characterized by the presence of a few companies. These vendors compete against each other based on factors such as aggressive pricing, product efficacy, limited side effects, rich pipeline, and an operational base. They are also focusing on research and developmental activities to remain competitive in the market.

Key vendors in this market are 

• Astellas Pharma
• Johnson & Johnson
• Sanofi
• Valeant

Other prominent vendors in the market include Active Biotech, Advaxis, ANI Pharmaceuticals, Athenex, Bavarian Nordic, Bayer, Bristol-Myers Squibb, CureVac, GlaxoSmithKline, Innocrin Pharmaceutical, Merck, Myovant Sciences, Northwest Biotherapeutics, OncoGenex Pharmaceuticals, Oncolytics Biotech, Orion, Sotio, Madrigal Pharmaceuticals, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.

Segmentation by therapy and analysis of the CRPC treatment market

• Hormonal therapy
• Chemotherapy

The hormonal therapy is also known as androgen suppression therapy or androgen deprivation therapy (ADT). This therapy helps in the reduction of testosterone levels in males by using several pharmacologic agents. The segment will continue to grow during the estimated period due to the availability of hormonal therapies such as Johnson & Johnson's ZYTIGA and Astellas' XTANDI.

Segmentation by geography and analysis of the CRPC treatment market

• Americas
• APAC
• EMEA

The Americas is witnessing an increasing demand for CRPC treatment due to the rising prevalence rate of prostate cancer. Prostate cancer is considered the second common cancer that highly affects the male population in the US. The adoption of CRPC treatment will continue to increase in the region by 2021 due to the growing demand for novel hormonal therapies.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global castration-resistant prostate cancer (CRPC) treatment market?
• What are the key market trends impacting the growth of the global castration-resistant prostate cancer (CRPC) treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global castration-resistant prostate cancer (CRPC) treatment market?
• What are the market opportunities and threats faced by the vendors in the global castration-resistant prostate cancer (CRPC) treatment market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global castration-resistant prostate cancer (CRPC) treatment market?

Technavio also offers customization on reports based on specific client requirement.